Purpose of this Study
Participants will be admitted to the Duke Early Phase Unit for 2 nights, and receive an infusion of either the study drug or placebo. Safety will be monitored for at least 24 hours after the infusion, and there will be numerous blood draws.
Who Can Participate?
Eligibility
People can join this study if they have HIV and are already taking medicine to control it. They must be generally healthy and not have major health problems affecting the heart, lungs, stomach, kidneys, skin, or liver. They also cannot have had cancer in the past three years.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is testing a new kind of medicine for people with HIV. The medicine is designed to find and target HIV that is hiding quietly inside the body. Researchers want to learn if this new drug is safe and figure out the best dose to use. The goal is to use this medicine along with regular HIV treatments to try to remove all HIV from the body in the future.
Locations
Duke University Hospital
Other
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
DIA04 IAP086-1: A Phase 1 Single Ascending Dose First-Time in Human Study of the Safety, Tolerability and Pharmacokinetics of IAP086 in Persons with HIV-1 on Antiretroviral Therapy
Principal Investigator
Shruti
Raja
Protocol Number
PRO00119783
Phase
I
Enrollment Status
Open to Enrollment